Annual Congress of the European Association of Nuclear Medicine October 12 – 16, 2019 Barcelona, Spain.
Is to design personalised, super-selective therapies and to identify more precise means of monitoring response to treatment in routine The now well-established tracks M2M - Molecule to Man (basic and translational science) and Do.MoRe (radionuclide therapy and dosimetry) promise to promote high-qual...
| Publicado en: | European Journal of Nuclear Medicine & Molecular Imaging Vol. 46; pp. 1 - 953 |
|---|---|
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Oct2019 Supplement 1
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Sumario: | Is to design personalised, super-selective therapies and to identify more precise means of monitoring response to treatment in routine The now well-established tracks M2M - Molecule to Man (basic and translational science) and Do.MoRe (radionuclide therapy and dosimetry) promise to promote high-quality research through interaction between basic and translational clinical Scientists and to present the latest achievements and developments in the fields of clinical molecular imaging and nuclear medicine therapy. Radiobiology and Dosimetry for Radioembolisation Therapy Problems Related to Dosimetry for Therapy Based on. |
|---|